

UNCLASSIFIED

Exhibit R-2, RDT&E Budget Item Justification: PB 2024 Army **Date:** March 2023

Appropriation/Budget Activity 2040: <i>Research, Development, Test & Evaluation, Army / BA 4: Advanced Component Development & Prototypes (ACD&P)</i>	R-1 Program Element (Number/Name) PE 0603807A / <i>Medical Systems - Adv Dev</i>
---	--

COST (\$ in Millions)	Prior Years	FY 2022	FY 2023	FY 2024 Base	FY 2024 OCO	FY 2024 Total	FY 2025	FY 2026	FY 2027	FY 2028	Cost To Complete	Total Cost
Total Program Element	-	27.768	5.598	1.602	-	1.602	0.596	1.038	1.050	1.062	0.000	38.714
808: <i>DoD Drug & Vacc Ad</i>	-	6.297	0.403	0.422	-	0.422	0.432	0.442	0.448	0.453	0.000	8.897
836: <i>Field Medical Systems Advanced Development</i>	-	20.071	5.195	1.180	-	1.180	0.164	0.596	0.602	0.609	0.000	28.417
FF4: <i>Counterdrug, DDR, Sys Development & Demonstration</i>	-	1.400	-	-	-	-	-	-	-	-	0.000	1.400

A. Mission Description and Budget Item Justification

This Program Element (PE) funds development of medical materiel within the early system integration portion of the System Development and Demonstration phase of the acquisition life cycle using 6.4 (Advanced Component Development and Prototype) funding. Program efforts support transition of promising Science and Technology candidate medical technologies (drugs, vaccines, medical devices, diagnostics, and mechanisms for detection and control of disease carrying insects) to larger scale testing in humans for safety and effectiveness. Programs are aligned to meet future force requirements identified within concept documents and organizational structures. This PE also provides funding for Food and Drug Administration (FDA) regulated human clinical trials to gain additional information about safety and effectiveness on the path to licensure for use in humans. These efforts are managed by U.S. Army Medical Materiel Development Activity (USAMMDA) of the U.S. Army Medical Research and Development Command.

B. Program Change Summary (\$ in Millions)

	<u>FY 2022</u>	<u>FY 2023</u>	<u>FY 2024 Base</u>	<u>FY 2024 OCO</u>	<u>FY 2024 Total</u>
Previous President's Budget	37.053	0.598	1.619	-	1.619
Current President's Budget	27.768	5.598	1.602	-	1.602
Total Adjustments	-9.285	5.000	-0.017	-	-0.017
• Congressional General Reductions	-	-			
• Congressional Directed Reductions	-	-			
• Congressional Rescissions	-	-			
• Congressional Adds	-	5.000			
• Congressional Directed Transfers	-	-			
• Reprogrammings	-9.285	-			
• SBIR/STTR Transfer	-	-			
• Adjustments to Budget Years	-	-	-0.017	-	-0.017

Congressional Add Details (\$ in Millions, and Includes General Reductions)

Project: 836: *Field Medical Systems Advanced Development*

Congressional Add: *Program increase - wearable medical device for TBI prevention*

FY 2022	FY 2023
5.000	5.000

UNCLASSIFIED

Exhibit R-2, RDT&E Budget Item Justification: PB 2024 Army	Date: March 2023
---	-------------------------

Appropriation/Budget Activity 2040: <i>Research, Development, Test & Evaluation, Army / BA 4: Advanced Component Development & Prototypes (ACD&P)</i>	R-1 Program Element (Number/Name) PE 0603807A / <i>Medical Systems - Adv Dev</i>
---	--

Congressional Add Details (\$ in Millions, and Includes General Reductions)

	FY 2022	FY 2023
Congressional Add Subtotals for Project: 836	5.000	5.000
Congressional Add Totals for all Projects	5.000	5.000

Change Summary Explanation

Decreased funding to support higher Army priorities.

UNCLASSIFIED

Exhibit R-2A, RDT&E Project Justification: PB 2024 Army										Date: March 2023		
Appropriation/Budget Activity 2040 / 4					R-1 Program Element (Number/Name) PE 0603807A / <i>Medical Systems - Adv Dev</i>				Project (Number/Name) 808 / <i>DoD Drug & Vacc Ad</i>			
COST (\$ in Millions)	Prior Years	FY 2022	FY 2023	FY 2024 Base	FY 2024 OCO	FY 2024 Total	FY 2025	FY 2026	FY 2027	FY 2028	Cost To Complete	Total Cost
808: <i>DoD Drug & Vacc Ad</i>	-	6.297	0.403	0.422	-	0.422	0.432	0.442	0.448	0.453	0.000	8.897
Quantity of RDT&E Articles	-	-	-	-	-	-	-	-	-	-		

A. Mission Description and Budget Item Justification

This Project funds development of candidate medical countermeasures for endemic infectious diseases of military relevance. These efforts are in: vaccines, drugs, diagnostic kits/devices. These funds support human clinical effectiveness (capacity to produce a desired size of an effect under ideal or optimal conditions) trials of the drug/vaccine in larger groups that are designed to assess how well the drug/vaccine works and continue safety assessments in a larger group of volunteers. Funding supports both technical evaluations and human clinical testing to assure the safety and effectiveness of medical diagnostic kits and devices. This work, which is performed in military laboratories or civilian pharmaceutical firms, is directed toward the prevention of disease, early diagnosis, and accelerated recovery time once diagnosed to enhance battlefield readiness. All clinical trials are conducted in accordance with United States (U.S.) Food and Drug Administration (FDA) regulations, a mandatory obligation for all military products placed into the hands of medical providers or service members. Product development priorities are determined based upon four major factors: (1) the extent and threat of the disease within the Combatant Commands theater of operations, (2) the clinical severity of the disease, (3) the technical maturity of the proposed solution, and (4) the affordability of the solution (development and production). Products from this Project will transition to PE 0604807A/Project 849 at MS B.

B. Accomplishments/Planned Programs (\$ in Millions)

	FY 2022	FY 2023	FY 2024
Title: DoD Drug and Vaccine Advanced Development - Medical Readiness	-	0.366	0.422
Description: Funding is provided for the development of candidate medical countermeasures for military relevant infectious disease focusing on prevention to increase medical readiness. Funding supports both technical evaluations and human clinical testing to assure the safety and effectiveness of drugs, vaccines, medical diagnostic kits and devices			
FY 2023 Plans: Provides Civilian Manpower support for Warfighter Health, Performance and Evacuation Project Management Office			
FY 2024 Plans: Will provide Civilian Manpower support for Warfighter Health, Performance and Evacuation Project Management Office			
FY 2023 to FY 2024 Increase/Decrease Statement: Increase in funding is for the adjustment of Civilian Manpower from FY23 to FY24.			
Title: DoD Drug and Vaccine Advanced Development - Battlefield Care and Return to Fight	6.297	-	-
Description: Funding is provided for the development of candidate medical countermeasures for military relevant infectious disease focusing on early diagnosis and accelerated recovery time. Funding supports both technical evaluations and human clinical testing to assure the safety and effectiveness of drugs, vaccines, medical diagnostic kits and devices			

UNCLASSIFIED

Exhibit R-2A, RDT&E Project Justification: PB 2024 Army	Date: March 2023
--	-------------------------

Appropriation/Budget Activity 2040 / 4	R-1 Program Element (Number/Name) PE 0603807A / <i>Medical Systems - Adv Dev</i>	Project (Number/Name) 808 / <i>DoD Drug & Vacc Ad</i>
--	--	---

B. Accomplishments/Planned Programs (\$ in Millions)	FY 2022	FY 2023	FY 2024
Title: SBIR/STTR	-	0.037	-
FY 2023 Plans: Funding transferred in accordance with Title 15 USC §638.			
FY 2023 to FY 2024 Increase/Decrease Statement: Funding transferred in accordance with Title 15 USC §638.			
Accomplishments/Planned Programs Subtotals	6.297	0.403	0.422

C. Other Program Funding Summary (\$ in Millions)

N/A

Remarks

D. Acquisition Strategy

Test and evaluate in-house and commercially developed products in extensive commercial partner or government-managed clinical trials to gather data required for FDA licensure ensuring government (military) requirements are met with judicious investment.

UNCLASSIFIED

Exhibit R-3, RDT&E Project Cost Analysis: PB 2024 Army **Date:** March 2023

Appropriation/Budget Activity 2040 / 4	R-1 Program Element (Number/Name) PE 0603807A / Medical Systems - Adv Dev	Project (Number/Name) 808 / DoD Drug & Vacc Ad
--	---	--

Management Services (\$ in Millions)				FY 2022		FY 2023		FY 2024 Base		FY 2024 OCO		FY 2024 Total	Cost To Complete	Total Cost	Target Value of Contract
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost			
Medical Product Development Management Services Cost	Various	Not Applicable : Not applicable	33.331	0.528		0.366		0.422		-		0.422	Continuing	Continuing	Continuing
Medical Product Development Management Services Cost	PO	General Dynamics Information Technology, : Frederick MD	11.454	1.001		-		-		-		-	0.000	12.455	-
SBIR/STTR Transfer	Various	Various : Various	-	-		0.037		-		-		-	0.000	0.037	-
Subtotal			44.785	1.529		0.403		0.422		-		0.422	Continuing	Continuing	N/A

Product Development (\$ in Millions)				FY 2022		FY 2023		FY 2024 Base		FY 2024 OCO		FY 2024 Total	Cost To Complete	Total Cost	Target Value of Contract
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost			
Rapid Human Diagnostics	Various	Cepheid : CA	2.142	1.300		-		-		-		-	0.000	3.442	-
Treatment for Drug Resistant Battlefield Bacterial Wound Infections	Various	TBD : TBD	-	1.156		-		-		-		-	0.000	1.156	-
Broad Spectrum Antiviral Therapeutic	Various	JHU/APL : Various	-	1.156		-		-		-		-	0.000	1.156	-
Treatment for Drug Resistant Battlefield Wound Infections	C/FFP	Gryphon Scientific LLC : MD	-	1.156		-		-		-		-	0.000	1.156	-
Subtotal			2.142	4.768		-		-		-		-	0.000	6.910	N/A

Project Cost Totals	Prior Years	FY 2022	FY 2023	FY 2024 Base	FY 2024 OCO	FY 2024 Total	Cost To Complete	Total Cost	Target Value of Contract
	46.927	6.297	0.403	0.422	-	0.422	Continuing	Continuing	N/A

Remarks

UNCLASSIFIED

Exhibit R-4, RDT&E Schedule Profile: PB 2024 Army **Date:** March 2023

Appropriation/Budget Activity 2040 / 4	R-1 Program Element (Number/Name) PE 0603807A / <i>Medical Systems - Adv Dev</i>	Project (Number/Name) 808 / <i>DoD Drug & Vacc Ad</i>
--	--	---

Event Name	FY 2022				FY 2023				FY 2024				FY 2025				FY 2026				FY 2027				FY 2028			
	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4
Treatment for Drug Resistant Battlefield Fungal Wound In...																												
Rapid Human Diagnostic																												
Treatment for Drug Resistant Battlefield Wound Infections																												
Broad Spectrum Antiviral Therapeutic																												

UNCLASSIFIED

Exhibit R-4A, RDT&E Schedule Details: PB 2024 Army **Date:** March 2023

Appropriation/Budget Activity 2040 / 4	R-1 Program Element (Number/Name) PE 0603807A / <i>Medical Systems - Adv Dev</i>	Project (Number/Name) 808 / <i>DoD Drug & Vacc Ad</i>
--	--	---

Schedule Details

Events	Start		End	
	Quarter	Year	Quarter	Year
Treatment for Drug Resistant Battlefield Fungal Wound Infections	3	2021	4	2022
Rapid Human Diagnostic	4	2017	4	2022
Treatment for Drug Resistant Battlefield Wound Infections	4	2022	4	2022
Broad Spectrum Antiviral Therapeutic	4	2022	4	2022

UNCLASSIFIED

Exhibit R-2A, RDT&E Project Justification: PB 2024 Army										Date: March 2023		
Appropriation/Budget Activity 2040 / 4					R-1 Program Element (Number/Name) PE 0603807A / <i>Medical Systems - Adv Dev</i>				Project (Number/Name) 836 / <i>Field Medical Systems Advanced Development</i>			
COST (\$ in Millions)	Prior Years	FY 2022	FY 2023	FY 2024 Base	FY 2024 OCO	FY 2024 Total	FY 2025	FY 2026	FY 2027	FY 2028	Cost To Complete	Total Cost
836: <i>Field Medical Systems Advanced Development</i>	-	20.071	5.195	1.180	-	1.180	0.164	0.596	0.602	0.609	0.000	28.417
Quantity of RDT&E Articles	-	-	-	-	-	-	-	-	-	-		

A. Mission Description and Budget Item Justification

This Project funds the demonstration and validation of medical products for enhanced combat casualty care and follow-on care. This Project funds human clinical trials to test the safety and effectiveness of biologics (products derived from living organisms) and devices necessary to meet medical requirements. The Project Manager (PM) also considers factors to reduce the medical logistics footprint through smaller weight, volume, and equipment independence from supporting materials. All clinical trials are conducted in accordance with U.S. FDA regulations. Products from this project will transition to PE 0604807A/Project 832.

B. Accomplishments/Planned Programs (\$ in Millions)

	FY 2022	FY 2023	FY 2024
Title: Field Medical Systems Advanced Development - Medical Readiness	4.103	0.195	1.180
Description: Funding is provided for engineering and manufacturing development of medical products for diagnostic devices and testing of medical devices for use in the field. This project provides for the advanced product development and prototyping of Army lifesaving medical field systems. Project supports development and testing of medical products and equipment for deployable forces providing future interoperability of systems on the battlefield and situational awareness of Soldier well-being. Project supports enhancements to Soldier battlefield effectiveness, survivability, and sustainment. This project also supports joint medical field systems and prolonged combat casualty care requirements.			
FY 2023 Plans: Soldier Optimization Decision Aids (SODA): Initiate Software Design, Development, Test Planning, Acquisition Documentation, and Life Cycle Support of Mission planning mobile software apps that give Commanders the tools capable of optimizing Soldier potential and reducing the risk of costly non-battle injuries			
Non-invasive Neuro Assessment Devices (NINAD): Funding and mission realigned as part of US Army Medical Research and Development Command transfer to the Defense Health Agency in order to meet Congressional intent as outlined in National Defense Authorization Act 2019 (Sections 711) and NDAA 2020 (Section 737). Funding transferred to Program Element 0604110DHA, Project Code 374E.			
FY 2024 Plans: Medical Health Applications: Transitioned more advanced apps from 6.4 - 836 to 832. Will finalize software design, development, test planning, acquisition documentation, and life cycle support of mission planning mobile software apps that give Commanders			

UNCLASSIFIED

Exhibit R-2A, RDT&E Project Justification: PB 2024 Army		Date: March 2023
Appropriation/Budget Activity 2040 / 4	R-1 Program Element (Number/Name) PE 0603807A / <i>Medical Systems - Adv Dev</i>	Project (Number/Name) 836 / <i>Field Medical Systems Advanced Development</i>

B. Accomplishments/Planned Programs (\$ in Millions)	FY 2022	FY 2023	FY 2024
the tools capable of optimizing Soldier performance and readiness and reducing the risk of costly non-battle injuries related to mental acuity, fatigue management and arctic warfare. Arctic Medical Capabilities: Will develop a family of casualty care and prevention systems for operation in extreme cold weather per 2021 U.S. Army Arctic Strategy, "Regaining Arctic Dominance". FY 2023 to FY 2024 Increase/Decrease Statement: Funding increase in FY24 is due to emerging Arctic requirements.			
Title: Field Medical Systems Advanced Development - Battlefield Care and Return to Fight Description: Funding is provided for the development of the medical devices and blood products in support of enhanced combat casualty care.	5.819	-	-
Title: Field Medical Systems Advanced Development - Field Hospital and Evacuation Description: Funding is provided for the development of medical devices in support of the medical mission field hospitalization and evacuation.	5.149	-	-
Accomplishments/Planned Programs Subtotals	15.071	0.195	1.180

	FY 2022	FY 2023
Congressional Add: Program increase - wearable medical device for TBI prevention FY 2022 Accomplishments: Continue development and systems engineering of "Wearable TBI Device" to fulfill US Military-unique needs for TBI prevention; including developmental testing, pre-clinical testing and prototype refinement, environmental testing to ensure conformance to specs, FDA meeting(s), and Military Utility Assessment (MUA) activities. FY 2023 Plans: Wearable medical device for TBI Prevention	5.000	5.000
Congressional Adds Subtotals	5.000	5.000

C. Other Program Funding Summary (\$ in Millions)

N/A
Remarks

UNCLASSIFIED

Exhibit R-2A, RDT&E Project Justification: PB 2024 Army		Date: March 2023
Appropriation/Budget Activity 2040 / 4	R-1 Program Element (Number/Name) PE 0603807A / <i>Medical Systems - Adv Dev</i>	Project (Number/Name) 836 / <i>Field Medical Systems Advanced Development</i>

D. Acquisition Strategy

Develop in-house or industrial prototypes in government-managed programs to meet military and regulatory requirements for production and fielding.

UNCLASSIFIED

Exhibit R-3, RDT&E Project Cost Analysis: PB 2024 Army												Date: March 2023			
Appropriation/Budget Activity				R-1 Program Element (Number/Name)				Project (Number/Name)							
2040 / 4				PE 0603807A / Medical Systems - Adv Dev				836 / Field Medical Systems Advanced Development							
Management Services (\$ in Millions)				FY 2022		FY 2023		FY 2024 Base		FY 2024 OCO		FY 2024 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
Medical Product Development Management Services Cost	Various	Not Applicable : Not applicable	48.882	1.564		-		0.466		-		0.466	Continuing	Continuing	Continuing
Medical Product Development Management Services Cost	C/IDIQ	Not applicable : Not applicable	2.295	0.150		-		-		-		-	0.000	2.445	-
Subtotal			51.177	1.714		-		0.466		-		0.466	Continuing	Continuing	N/A
Product Development (\$ in Millions)				FY 2022		FY 2023		FY 2024 Base		FY 2024 OCO		FY 2024 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
Temporary Corneal Repair	C/Various	Critical Innovations, LLC, GelMEDIX, Endomedix, Inc., Ashvattha Therapeutics, LLC , University of Southern California, Institute of Surgical Research : Inglewood, CA, Cambridge, MA, Montclair, NJ, Redwo	13.721	2.178		-		-		-		-	0.000	15.899	-
Non-invasive neuro assessment device (NINAD)	C/Various	TBD : TBD	0.800	1.471		-		-		-		-	0.000	2.271	-
Transport Telemedicine Systems (TTS) - MEDHUB Platform	TBD	Cooper Consulting Services : TBD	2.343	2.899		-		-		-		-	Continuing	Continuing	Continuing
Burn Treatment Skin Repair	TBD	TBD : TBD	-	2.760		-		-		-		-	0.000	2.760	-
Platelet-Derived Hemostatic Agent	TBD	TBD : TBD	-	0.316		-		-		-		-	0.000	0.316	-

UNCLASSIFIED

Exhibit R-3, RDT&E Project Cost Analysis: PB 2024 Army **Date:** March 2023

Appropriation/Budget Activity 2040 / 4	R-1 Program Element (Number/Name) PE 0603807A / Medical Systems - Adv Dev	Project (Number/Name) 836 / Field Medical Systems Advanced Development
--	---	--

Product Development (\$ in Millions)				FY 2022		FY 2023		FY 2024 Base		FY 2024 OCO		FY 2024 Total	Cost To Complete	Total Cost	Target Value of Contract
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost			
Program Increase - Wearable Medical Device for TBI prevention	TBD	TBD : TBD	3.000	5.000		5.000		-		-		-	0.000	13.000	-
Subtotal			19.864	14.624		5.000		-		-		-	Continuing	Continuing	N/A

Support (\$ in Millions)				FY 2022		FY 2023		FY 2024 Base		FY 2024 OCO		FY 2024 Total	Cost To Complete	Total Cost	Target Value of Contract
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost			
Medical Product Development Support Cost	Various	Not Applicable : Not applicable	52.372	1.842		-		-		-		-	Continuing	Continuing	Continuing
Medical Health Applications	TBD	TBD : TBD	-	-		0.195		0.714		-		0.714	0.000	0.909	-
Subtotal			52.372	1.842		0.195		0.714		-		0.714	Continuing	Continuing	N/A

Remarks
No product/contract costs greater than \$1M individually.

Test and Evaluation (\$ in Millions)				FY 2022		FY 2023		FY 2024 Base		FY 2024 OCO		FY 2024 Total	Cost To Complete	Total Cost	Target Value of Contract
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost			
Noninvasive Neuro-Assessment Devices (NINAD)	TBD	TBD : TBD	-	1.891		-		-		-		-	0.000	1.891	-
Subtotal			-	1.891		-		-		-		-	0.000	1.891	N/A

Remarks
No product/contract costs greater than \$1M individually.

UNCLASSIFIED

Exhibit R-4, RDT&E Schedule Profile: PB 2024 Army		Date: March 2023
Appropriation/Budget Activity 2040 / 4	R-1 Program Element (Number/Name) PE 0603807A / <i>Medical Systems - Adv Dev</i>	Project (Number/Name) 836 / <i>Field Medical Systems Advanced Development</i>

Event Name	FY 2022				FY 2023				FY 2024				FY 2025				FY 2026				FY 2027				FY 2028																							
	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4																				
Temporary Corneal Repair	R&D development																																															
Temporary Corneal Repair -Prototype Testing	Prototype Testing																																															
Temporary Corneal Repair- Clinical Study	Clinical Study																																															
Noninvasive Neuro Assessment Device development (NINAD)	R&D development																																															
Transport Telemedicine Systems (TTS)- MEDHUB Platform																																																
Burn Treatment Skin Repair	Prototype Development																																															
Medical Health Applications																																																

UNCLASSIFIED

Exhibit R-4A, RDT&E Schedule Details: PB 2024 Army		Date: March 2023
Appropriation/Budget Activity 2040 / 4	R-1 Program Element (Number/Name) PE 0603807A / <i>Medical Systems - Adv Dev</i>	Project (Number/Name) 836 / <i>Field Medical Systems Advanced Development</i>

Schedule Details

Events	Start		End	
	Quarter	Year	Quarter	Year
Temporary Corneal Repair	2	2016	4	2022
Temporary Corneal Repair -Prototype Testing	2	2018	4	2022
Temporary Corneal Repair- Clinical Study	2	2020	4	2022
Noninvasive Neuro Assessment Device development (NINAD)	1	2019	4	2022
Transport Telemedicine Systems (TTS)- MEDHUB Platform	3	2013	4	2022
Burn Treatment Skin Repair	1	2022	4	2022
Medical Health Applications	1	2023	4	2024

UNCLASSIFIED

Exhibit R-2A, RDT&E Project Justification: PB 2024 Army										Date: March 2023		
Appropriation/Budget Activity 2040 / 4					R-1 Program Element (Number/Name) PE 0603807A / <i>Medical Systems - Adv Dev</i>				Project (Number/Name) FF4 / <i>Counterdrug, DDR, Sys Development & Demonstration</i>			
COST (\$ in Millions)	Prior Years	FY 2022	FY 2023	FY 2024 Base	FY 2024 OCO	FY 2024 Total	FY 2025	FY 2026	FY 2027	FY 2028	Cost To Complete	Total Cost
<i>FF4: Counterdrug, DDR, Sys Development & Demonstration</i>	-	1.400	-	-	-	-	-	-	-	-	0.000	1.400
Quantity of RDT&E Articles	-	-	-	-	-	-	-	-	-	-		

A. Mission Description and Budget Item Justification

Supports the Secretary of Defense approved counterdrug advanced development efforts used in a major re-design of the Forensic Toxicology Drug Testing Laboratory (FTDTL) information management system used to test urine samples for the presence of illegal drugs. The Drug Testing Program - Client Collection System (DTP-CSS) is comprised of several variations of a desktop application used to select service members for random drug testing, prepare labels for urine specimen bottles, and print corresponding chain-of-custody documents. This Project will standardize DTP-CSS across all services and migrate it to a Web-based system.

B. Accomplishments/Planned Programs (\$ in Millions)

	FY 2022	FY 2023	FY 2024
Title: Forensic Toxicology Drug Testing Laboratory - Information Management System (FTDTL-IMS)	1.400	-	-
Accomplishments/Planned Programs Subtotals	1.400	-	-

C. Other Program Funding Summary (\$ in Millions)

N/A

Remarks

D. Acquisition Strategy

N/A

UNCLASSIFIED

Exhibit R-4, RDT&E Schedule Profile: PB 2024 Army			Date: March 2023		
Appropriation/Budget Activity 2040 / 4		R-1 Program Element (Number/Name) PE 0603807A / Medical Systems - Adv Dev		Project (Number/Name) FF4 / Counterdrug, DDR, Sys Development & Demonstration	

Event Name	FY 2022				FY 2023				FY 2024				FY 2025				FY 2026				FY 2027				FY 2028			
	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4
FTDTL-IMS Modernization																												

UNCLASSIFIED

Exhibit R-4A, RDT&E Schedule Details: PB 2024 Army		Date: March 2023
Appropriation/Budget Activity 2040 / 4	R-1 Program Element (Number/Name) PE 0603807A / <i>Medical Systems - Adv Dev</i>	Project (Number/Name) FF4 / <i>Counterdrug, DDR, Sys Development & Demonstration</i>

Schedule Details

Events	Start		End	
	Quarter	Year	Quarter	Year
FTDTL-IMS Modernization	1	2022	4	2022